Premium
Adverse hepatic events caused by radiotherapy for advanced hepatocellular carcinoma
Author(s) -
FURUSE JUNJI,
ISHII HIROSHI,
NAGASE MICHITAKA,
KAWASHIMA MITSUHIKO,
OGINO TAKASHI,
YOSHINO MASAHIRO
Publication year - 2005
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.2005.03916.x
Subject(s) - medicine , adverse effect , hypoalbuminemia , radiation therapy , hepatocellular carcinoma , ascites , liver function , gastroenterology , oncology , surgery
Abstract Background: Radiotherapy is often used to treat patients with unresectable advanced hepatocellular carcinoma (HCC). The present study examines the nature and frequency of adverse events with respect to liver function in such patients after radiotherapy. Methods: Forty‐six patients with HCC who underwent radiotherapy were retrospectively examined. Radiotherapy was applied using coplanar 2–3‐beam arrangements to a target dose of 50 Gy/5 weeks. The adverse hepatic events were evaluated according to the National Cancer Institute Common Toxicity Criteria and the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer Late Radiation Morbidity Scoring Scheme during the acute phase and the late phase by following the patients for up to 1 year. The influence on survival by adverse hepatic events and other factors was analyzed. Results: The full irradiation dose of 50 Gy was given to 40 patients (87.0%). Grade 3 or 4 toxicity was observed in 18 (39.1%) within 3 months after radiotherapy and in 11 (33.3%) of 33 thereafter, respectively. The most frequent and serious adverse events were hyperbilirubinemia, hypoalbuminemia, and ascites. The independent adverse prognostic factors for survival were portal vein tumor thrombus ( P = 0.0012), tumor response ( P = 0.011), acute adverse hepatic event ( P = 0.012), and late adverse hepatic event ( P = 0.015). Conclusions: Hypoalbuminemia, hyperbilirubinemia, and ascites were important hepatic adverse events that developed after applying radiotherapy to treat advanced HCC. These adverse events seriously affected survival.